Co-Hosting "The Pacific Connection: US-East Asia Pharma Collaboration"
Co-Hosted with New York Pharma Forum
February 11, 2015
12:30 PM - 4:15 PM
Yale Club Manhattan
12:30-1:00 PM Network Reception
1:00-1:10 PM Opening
DoHyun Cho, PhD
CEO and President, W Medical Strategy Group / Chairman, New York Health Forum
"The Pacific Connection: US-East Asia Pharma Collaboration"
Mark Dennish, MBA (Vice President, Business Development and New Product Planning, Daiichi Sankyo / Vice President, New York Pharma Forum Inc.)
"Shifting Market Priorities"
1:10-1:15 PM Supporting Remark
Chul S. Hyun, MD, PhD
President of World Korean Medical Organization (WKMO)
1:15-2:15 PM Session 1
"Diverse Tracks of Global Market: Journey of Chinese, Japanese, and Korean Pharma”
Mark Paxton, JD, EVP, W Medical Strategy Group (Moderator)
Mark Dennish, MBA, Vice President, Business Development and New Product Planning, Daiichi Sankyo (Japan)
Joy Wang, PhD, MBA, US office head of Simcere Pharmaceuticals (China)
Howard Kim, Director of Business Development, Yonsung Fine Chemicals (Korea)
2:15-3:15 PM Session 2
“Fitting into the Ecosystem: New Sustainable Strategies of Collaboration”
Kimberly Ha, Senior Director, FTI Consulting (Moderator)
Bryan Spielman, MBA, Executive Vice President, Medidata
Les Funtleyder, MPH, Portfolio Manager, Esquared Asset Management
Debra Yu, MD, Managing Director of Labrador Advisors
3:15-4:15 PM Session 3
"Expansion Strategies of East Asian Pharma Companies: Shifting the Paradigm"
Joe McMenamin, MD, JD, EVP, W Medical Strategy Group (Moderator)
Han Choi, MD, LLM, Principal, Oracle Investment Management
Young-Seok Byun, PhD, Head of R&D, UK ChemiPharm
Yuan-Hua Ding, PhD, Executive Director & Head, Asia/Pacific, Pfizer
4:15 PM Network Reception
Moderator: Mark S. Paxton, JD
Executive Vice President, W Medical Strategy Group
Mark S. Paxton is an Executive Vice President for W Medical Strategy Group. He was a Compliance officer of the US Food and Drug Administration and also served as Vice-President at PhRMA. Currently, he serves as editorial board member of World Korean Medical Journal.
Mark Dennish, MBA
Vice President, Business Development and New Product Planning, Daiichi Sankyo (Japan)
Mark Dennish joined Daiichi Sankyo in February 2008 and currently serves as Vice President, Business Development, where he is responsible for the full array of business development activities including Mergers & Acquisitions, Product Licensing, and R&D and Commercial Collaborations. He currently serves as a Board Member of the New York Pharma Forum.
Joy Wang, PhD, MBA
US office head of Simcere Pharmaceuticals (China)
Joy Wang is the Business Development Director of Simcere and BioSciKin, and the business head of the U.S. office. She is in charge of Simcere/BioSciKin overseas strategic cooperation and licensing in the United States and Europe. Joy has over 10 years of experience in the pharmaceutical industry.
Director of Business Development, Yonsung Fine Chemicals (Korea)
Howard Kim is currently the Director of Business Development at Yonsung Fine Chemicals Co., Ltd. in Korea. He has been successful in developing businesses for prostaglandins and complicated APIs in the U.S. and in Europe. Howard spent over 30 years in sourcing for global pharmaceutical companies, including Novarties, Wyeth, and Merck in the areas of pharmaceutical, generic, veterinary, and OTC businesses.
Moderator: Kimberly Ha
Senior Director, FTI Consulting
Kimberly Ha is currently Senior Director at FTC Consulting, Strategic Communications. Her focus area is Capital Markets and Healthcare. She was previously Global Editor for BioPharm Insight, an independent business intelligence product launched by the Financial Time Group. Kimberly has been a panelist and moderator at major healthcare conferences and events.
Bryan Spielman, MBA
Executive Vice President, Strategy and Corporate Development, Medidata
Bryan Spielman, EVP of Medidata, is in charge of strategy and corporate development. He crafts Medidata’s corporate strategy, developing relationships with industry and financial communities, and driving strategic partnerships, mergers and acquisition, joint ventures and other related transactions. Previously, he was a founding partner of the Technology Investment Banking Team at Centerview Partners. He’s also held leadership roles at the Technology Investment Banking Groups at UBS Investment Bank and Bear Steams.
Les Funtleyder, MPH
Portfolio Manager, Esquared Asset Management
Les Funtleyder is currently a portfolio manager at E Squared Asset Management. He is an experienced healthcare investor and analyst with a track record of significant positive returns across Pharmaceuticals, Medical Technology, Managed Care, Hospitals and other facilities, and Healthcare Information Technology, Managed Care, Hospitals and other facilities, and Healthcare Information Technology utilizing public equity, private equity, and debt. Les Funtleyder has served as a speaker and resource to media, policymakers, and corporations on the intersection of investing, health policy and innovation. Les is the author of Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health-Care Services (McGraw Hill, 2009).
Debra Yu, MD
Managing Director of Labrador Advisors
Debra Yu is Managing Director of Labrador Advisors, a life sciences advisory firm that works with companies on corporate development, business development, and strategy. In this capacity, she works with leading pharma, biotech companies and on partnering, M&A and other transactions. She served as a General Partner of Delphi Ventures as the first Managing Directors of Bay City Capital and then built Pfizer’s corporate venture capital group which she co-led for 5 years.
Moderator: Joseph P. McMenamin, MD, JD
Chief Legal Officer, W Medical Strategy Group
Joseph P. McMenamin is the Chief Legal Officer of W Medical Strategy Group. He has more than 25 years of experience in defending biotech, pharmaceutical, and other healthcare organizations against a variety of allegations in state and federal court.
Han Choi, MD, LLM
Principal, Oracle Investment Management
Han Choi is a Principal at Oracle Investment Management, a health care hedge fund based in Greenwich, CT. Prior to joining Oracle, he held positions of increasing responsibility in business development and licensing at Pharmacia Corporation (now Pfizer Inc.) and Bristol-Myers Squibb Company. He also served as an Epidemic Intelligence Service Officer at the U.S. CDC and Prevention.
Young-Seok Byun, PhD
Head of R&D, UK ChemiPharm
Young-Seok Byun is a Research Director at UK Chemipharm, a pharmaceutical company based in South Korea. Prior to joining UK Chemipharm, he was a head researcher at Jaeil Pharmaceutical Company and Daewoong Pharmaceutical Company in South Korea. He is in charge of R&D part of API. Young-Seok received his Ph.D. from Univ. Nevada, Reno, in chemistry.
Yuan-Hua Ding, PhD
Executive Director & Head, Asia/Pacific, Pfizer
Yuan-Hua Ding is an Executive Director and Head of Pfizer External R&D Innovation (ERDI) – Asia/Pacific, Pfizer Worldwide Research & Development (WRD). His team collaborates with Pfizer internal scientific and BD colleagues to evaluate technologies and assets from Asia Pacific regions, seek opportunities to incubate early biotech companies, build and manage a research network of academic institutes, biotech & pharma companies, and venture capital groups as well as regional bioparks.